WO2024027901A1 - Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 - Google Patents
Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 Download PDFInfo
- Publication number
- WO2024027901A1 WO2024027901A1 PCT/EP2022/071618 EP2022071618W WO2024027901A1 WO 2024027901 A1 WO2024027901 A1 WO 2024027901A1 EP 2022071618 W EP2022071618 W EP 2022071618W WO 2024027901 A1 WO2024027901 A1 WO 2024027901A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- value
- subject
- treatment
- Prior art date
Links
- 230000004044 response Effects 0.000 title claims abstract description 35
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title claims abstract description 28
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title claims abstract description 28
- 239000000092 prognostic biomarker Substances 0.000 title description 5
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 129
- 150000001875 compounds Chemical class 0.000 claims abstract description 127
- 238000000034 method Methods 0.000 claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 53
- 239000000090 biomarker Substances 0.000 claims abstract description 51
- 210000004369 blood Anatomy 0.000 claims abstract description 35
- 239000008280 blood Substances 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 210000003979 eosinophil Anatomy 0.000 claims description 56
- 210000002966 serum Anatomy 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 35
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 22
- 206010006451 bronchitis Diseases 0.000 claims description 22
- 208000007451 chronic bronchitis Diseases 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 6
- 208000000884 Airway Obstruction Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 102400001355 Interleukin-8 Human genes 0.000 description 94
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 89
- 229940096397 interleukin-8 Drugs 0.000 description 88
- 230000005713 exacerbation Effects 0.000 description 56
- 239000000902 placebo Substances 0.000 description 37
- 229940068196 placebo Drugs 0.000 description 37
- 239000011230 binding agent Substances 0.000 description 33
- 102000004890 Interleukin-8 Human genes 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 230000009467 reduction Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 13
- 238000009739 binding Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 102400001232 IL-8(6-77) Human genes 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 7
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 101500025785 Homo sapiens IL-8(6-77) Proteins 0.000 description 6
- 238000004590 computer program Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 4
- 101500025787 Homo sapiens Interleukin-8 Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 102400001231 IL-8(7-77) Human genes 0.000 description 3
- 102400001230 IL-8(8-77) Human genes 0.000 description 3
- 102100026236 Interleukin-8 Human genes 0.000 description 3
- 102400001235 MDNCF-a Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 3
- 229960002586 roflumilast Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- -1 sulphonamido Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101500025794 Homo sapiens IL-8(7-77) Proteins 0.000 description 2
- 101500025792 Homo sapiens IL-8(8-77) Proteins 0.000 description 2
- 101500025793 Homo sapiens IL-8(9-77) Proteins 0.000 description 2
- 101500025786 Homo sapiens MDNCF-a Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101800002919 IL-8(6-77) Proteins 0.000 description 2
- 102400001229 IL-8(9-77) Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- VCFBPAOSTLMYIV-SANMLTNESA-N [(1s)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-(cyclopropylmethoxy)-4-(methanesulfonamido)benzoate Chemical compound CS(=O)(=O)NC1=CC=C(C(=O)O[C@@H](CC=2C(=C[N+]([O-])=CC=2Cl)Cl)C=2C=C(OCC3CC3)C(OC(F)F)=CC=2)C=C1OCC1CC1 VCFBPAOSTLMYIV-SANMLTNESA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- VCFBPAOSTLMYIV-AREMUKBSSA-N tanimilast Chemical compound CS(=O)(=O)NC1=C(OCC2CC2)C=C(C=C1)C(=O)O[C@H](CC1=C(Cl)C=[N+]([O-])C=C1Cl)C1=CC(OCC2CC2)=C(OC(F)F)C=C1 VCFBPAOSTLMYIV-AREMUKBSSA-N 0.000 description 2
- 229940020042 tanimilast Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003519 ventilatory effect Effects 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical class C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101150059044 CXCL8 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102400001233 IL-8(5-77) Human genes 0.000 description 1
- 101800004598 IL-8(5-77) Proteins 0.000 description 1
- 101800003411 IL-8(7-77) Proteins 0.000 description 1
- 101800003927 IL-8(8-77) Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101800002493 MDNCF-a Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HJCUTNIGJHJGCF-UHFFFAOYSA-N acridan acid Natural products C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002503 iridium Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000001384 succinic acid Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the present invention relates to the use of IL-8 as a biomarker of clinical response to a compound of formula (I). It refers to a compound of formula (I) or a pharmaceutical composition thereof for use in a method of treatment of a disorder susceptible to treatment with a PDE4 inhibitor, wherein the method comprises the step of measuring the value of IL-8 in the blood of a subject and to a method to identify a subject to be treated with a compound of formula (I) or a pharmaceutical composition.
- Interleukin-8 is a chemoattractant cytokine produced by a variety of tissue and blood cells. Unlike many other cytokines, it has a distinct target specificity for the neutrophil, with only weak effects on other blood cells. Interleukin-8 attracts and activates neutrophils in inflammatory regions. IL-8 is initially produced as a precursor peptide of 99 amino acids which then undergoes cleavage to create several active IL-8 isoforms.
- Interleukin-8 is a member of the Interleukin-8 supergene family that includes other small chemotactic peptides with structural homology. It also shares with other cytokines DNA sequence features that suggest common regulatory pathways. In humans, the interleukin-8 protein is encoded by the CXCL8 gene.
- IL-8 In vivo intracutaneous application of IL-8 induces local exudation and a massive, long-lasting accumulation of neutrophils. Although IL-8 plays a role in the cytokine network, its major pathophysiological role lies in affecting neutrophils.
- Airway obstruction characterizes a number of severe respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Events leading to airway obstruction include oedema of airway walls, increased mucous production and inflammation.
- COPD chronic obstructive pulmonary disease
- COPD chronic respiratory disorder that progresses slowly and is characterised by an obstructive ventilatory pattern, which is rarely reversible, very often related to tobacco smoking and which can lead to chronic respiratory failure.
- This definition covers chronic bronchitis, with an obstructive ventilatory pattern that is defined by the existence of chronic bronchitis with permanent obstruction of airways.
- COPD is currently ranked as the fourth leading cause of death in the US and is predicted to become the third leading cause of death worldwide by 2030. More than 16.4 million people in the US have been diagnosed with COPD, but it is estimated that millions more have yet to be diagnosed (American Lung Association. How serious is COPD; 2019). The global COPD burden is projected to increase (Mathers C, Loncar D.
- biomarkers have long been used in drug development, and the discovery and validation of new efficacy biomarkers is expected to improve the predictive disease models, reduce the time and cost associated with drug development, and increase the success rate of translating experimental drugs into clinical therapeutics.
- biomarkers are valuable in early detection of disease development, changes in disease status, and effectiveness of behavioral modifications and therapeutics in disease control.
- PDE4 phosphodiesterase enzymes
- the compound of formula (I) also named Tanimilast or CHF6001 or CHF-6001, with INN (3,5-dichloro-4-[(2S)- 2-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2- ⁇ [3-(cyclopropylmethoxy)- 4-(methanesulfonamido)benzoyl]oxy ⁇ ethyl]pyridinel -oxide), is an highly potent and selective PDE4 inhibitor with robust anti-inflammatory activity, currently under clinical development.
- Roflumilast is Among other PDE4 inhibitors, Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD and method for selecting patients suffering from COPD with rare exacerbations to be treated with Roflumilast is known in the art and disclosed in RU2726228.
- the method comprises assessing a patient's quality of life using a CAT test and sampling blood to measure serum levels of tumor necrosis factor-alpha and interleukin-8.
- blood IL-8 value represents a predictive biomarker of enhanced clinical response to the compound of formula (I).
- COPD patients with a blood IL-8 value lower or equal to a reference value are shown to have an increased response to the compound of formula (I) treatment in terms of moderate-to-severe exacerbation rate reduction as well as in delay of time to first moderate-to-severe exacerbation.
- the present invention relates to a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier for use in a method of treatment of a disorder susceptible to treatment with a PDE4 inhibitor, wherein the method comprises the step of measuring the value of IL-8 in the blood of a subject, and comparing the measured value to a reference IL-8 value wherein if the measured value is lower or equal to said reference value the subject is treated.
- the present invention refers to a method to identify a subject to be treated with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier wherein said subject is afflicted with a disorder susceptible to treatment with a PDE4 inhibitor, the method comprising the step of measuring the value of IL-8 in the blood of the subject, and comparing the measured value to a reference IL-8 value, wherein, if the measured value is lower or equal to said reference value, then the subject is identified.
- the present invention refers to a method for treating a subject with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier wherein the subject afflicted with a disorder susceptible to treatment with a PDE4 inhibitor, the method comprising the steps of: a) identifying a subject to be treated with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier according to the method defined above and b) administering a therapeutic amount of a compound of formula (I) or the pharmaceutical composition to the subject.
- Fig. 1 A -Adjusted annualised moderate-to-severe exacerbation rate (with 95% CI) in the overall population and in subgroups of patients characterised by low serum interleukin-8 levels at baseline ⁇ statistically significantly different versus placebo, p ⁇ 0.05).
- B Adjusted annualised moderate-to-severe exacerbation rate (with 95% CI) in patients with a chronic bronchitis phenotype (CB) and with different serum interleukin- 8 levels at baseline ⁇ statistically significantly different versus placebo, p ⁇ 0.05).
- CB chronic bronchitis phenotype
- Fig. 2 A -Adjusted % reduction vs placebo of the moderate-to-severe exacerbation rate in the overall population and in subgroups of patients characterised by low serum interleukin-8 levels at baseline (* exacerbation rate statistically significantly different versus placebo, p ⁇ 0.05).
- B Adjusted % reduction vs placebo of the moderate-to-severe exacerbation rate in patients with a chronic bronchitis phenotype and with different serum interleukin-8 levels at baseline (*exacerbation rate statistically significantly different versus placebo, p ⁇ 0.05).
- Fig. 3 Al A2, A3, A4 - Kaplan-Meier curve for time to first moderate-to-severe exacerbation event during the 24-week treatment period in the overall population and in subgroups of patients characterised by lower serum interleukin-8 levels at baseline (*risk of experiencing a moderate-to-severe exacerbation over time statistically significantly different versus placebo, p ⁇ 0.05).
- Bl, B2, B3, B4 - Kaplan-Meier curve for time to first moderate-to-severe exacerbation event during the 24-week treatment period in patients with a chronic bronchitis phenotype and with different serum interleukin-8 levels at baseline (*risk of experiencing a moderate-to-severe exacerbation over time statistically significantly different versus placebo, p ⁇ 0.05).
- the compound of formula (I) of the present invention is intended to include also stereoisomers, tautomers or pharmaceutically acceptable salts or solvates thereof.
- pharmaceutically acceptable salts refers to derivatives of compounds of formula (I) wherein the parent compound is suitably modified by converting any of the free acid or basic group, if present, into the corresponding addition salt with any base or acid conventionally intended as being pharmaceutically acceptable.
- Suitable examples of said salts may thus include mineral or organic acid addition salts of basic residues such as amino groups, as well as mineral or organic basic addition salts of acid residues such as carboxylic groups.
- Cations of inorganic bases which can be suitably used to prepare salts comprise ions of alkali or alkaline earth metals such as potassium, sodium, calcium or magnesium.
- Those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt comprise, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, acetic acid, oxalic acid, maleic acid, fumaric acid, succinic acid and citric acid.
- solvate means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
- the solvate may comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules.
- stereoisomer refers to isomers of identical constitution that differ in the arrangement of their atoms in space. Enantiomers and diastereomers are examples of stereoisomers.
- racemate or “racemic mixture” refers to a composition composed of equimolar quantities of two enantiomeric species, wherein the composition is devoid of optical activity.
- tautomer refers to each of two or more isomers of a compound that exist together in equilibrium and are readily interchanged by migration of an atom or group within the molecule.
- biomarker or “marker” refers to an objectively measured indicator that reflects the successful treatment of a particular condition.
- IL-8 refers to Interleukin 8 (IL-8 or chemokine (C-X-C motif) ligand 8, CXCL8), preferably human IL-8.
- the sequence of the protein is well-known in the art and is, for example, accessible via Uni-Prot (UniProtKB - P10145 (IL8 HLTMAN) or via GenBank (NCBI Reference Sequence: NM_000584.4)).
- blood refers to serum, plasma, whole blood or PBMCs derived from the subject's blood.
- sample refers to the liquid fraction of whole blood that is obtained after the blood is allowed to clot.
- measuring the amount of a biomarker or “measuring the biomarker” as referred to herein refers to the quantification of the biomarker, e.g. to determining the level of the biomarker in the sample, employing appropriate methods of detection described herein below.
- the terms “measuring” and “determining” are used herein interchangeably.
- binding agent binds to a biomarker
- binding agent relates to an agent that comprises a binding moiety which specifically binds the corresponding biomarker.
- binding agents or “agents” are a nucleic acid probe, nucleic acid primer, DNA molecule, RNA molecule, aptamer, antibody, antibody fragment, peptide, peptide nucleic acid (PNA) or chemical compound.
- a preferred agent is an antibody which specifically binds to the biomarker to be measured.
- antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multi- specific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity (i.e. antigen-binding fragments thereof).
- the antibody is a polyclonal antibody. More preferably, the antibody is a monoclonal antibody.
- binding refers to a binding reaction wherein binding pair molecules exhibit a binding to each other under conditions where they do not significantly bind to other molecules.
- the term “specific binding” or “specifically binds” preferably refers to an affinity of at least 1 O' 8 M or even more preferred of at least 1 O' 9 M for its target molecule.
- the term “specific” or “specifically” is used to indicate that other molecules present in the sample do not significantly bind to the binding agent specific for the target molecule.
- the “value” or “expression” or “level” or “amount” of IL-8 relates to the amount of IL-8 polypeptide present in a sample or the amount of mRNA encoding IL-8 present in a sample.
- amount encompasses the absolute amount of a biomarker as referred to herein, the relative amount or concentration of the said biomarker as well as any value or parameter which correlates thereto or can be derived therefrom.
- comparing refers to comparing the amount of the biomarker in the sample from the subject with the reference amount of the biomarker specified elsewhere in this description. It is to be understood that comparing as used herein usually refers to a comparison of corresponding parameters or values, e.g., an absolute amount is compared to an absolute reference amount while a concentration is compared to a reference concentration or an intensity signal obtained from the biomarker in a sample is compared to the same type of intensity signal obtained from a reference sample.
- reference IL-8 amount or “reference IL-8 value” or “reference eosinophil amount” or “reference eosinophil value” as used herein refer to an amount which allows to identify a subject with enhanced response to compound of formula (I) and therefore to be treated with the same. Such terms may also refer to a predetermined value. Said predetermined value shall allow to identify a subject with enhanced response to compound of formula (I) and therefore to be treated with the same.
- An amount of IL- 8 in the sample of the test subject at or below the reference IL-8 amount indicates that the subject is lilely to have an enhanced response to the compound of formula (I).
- An amount of eosinophils in the sample of the test subject at or above the reference eosinophil amount indicates that the subject is lilely to have an enhanced response to compound of formula (I).
- Low or lower serum IL-8 levels means a serum level lower than or equal to about 23 pg/ml.
- “High or higher blood eosinophil count” means a blood eosinophil count higher than about 150 cells/pl.
- subject refers to a specific individual, preferably a mammal, more preferably a human, who is diagnosed with, or suspected of having, a disease or disorder and/or is under treatment for a disease or disorder susceptible of treatment with a PDE4 inhibitor.
- subject and patient are used interchangeably in this application.
- baseline or a subject at “baseline” is a subject prior to administration of the compound of formula (I).
- a “pharmaceutically acceptable carrier” refers to a carrier or excipient that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. It can be a pharmaceutically acceptable solvent, suspending agent or vehicle, for delivering the instant compounds to the subject.
- a “PDE4 inhibitor” is any molecule that blocks the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine monophosphate (cAMP), it prevents the breakdown of cAMP.
- a disorder susceptible to treatment with a PDE4 inhibitor is any disease wherein the activity of PDE4 receptors is implicated and inhibition of PDE4 receptor activity is desired or a disease state which is mediated by PDE4 activity, for instance a disease state in which PDE4 is overexpressed or overactive.
- COPD exacerbation is defined as a sustained worsening of the patient’s condition (dyspnoea, cough and/or sputum product! on/purulence), from the stable state and beyond normal day-to-day variations, that was acute in onset and necessitated a change in regular medication in a patient with underlying COPD that required prescriptions of systemic corticosteroids (oral/intravenous [IV]/intramuscular [IM] corticosteroids) and/or antibiotics (for a moderate exacerbation) or hospitalisation or leading to death (for severe exacerbation).
- systemic corticosteroids oral/intravenous [IV]/intramuscular [IM] corticosteroids
- antibiotics for a moderate exacerbation
- hospitalisation or leading to death for severe exacerbation
- “Mild exacerbation” is defined as exacerbations described as an increase in respiratory symptoms that can be controlled by the patient with an increase in usual medication;
- Modeerate exacerbation represents exacerbations that require treatment with systemic (oral/IV/IM corticosteroids) corticosteroids and/or antibiotics;
- Rate ratio refers to the ratio between annualised rate in the compound of formula (I) arm and annualised rate in the placebo arm. Percent reduction is derived as (1 - rate ratio) x 100. Adjusted rates are those derived from the negative binomial models.
- “Hazard ratio” is the conditional probability that the event will occur at time t given that it has not occurred prior to time t and it is computed as ratio between density function f(t) and survivor function S(t).
- the present invention refers to a method to identify a subject to be treated with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier wherein said subject is afflicted with a disorder susceptible to treatment with a PDE4 inhibitor, and wherein the method is characterized by the steps of:
- the inventors conducted a study to investigate the effect of said compound in comparison to placebo over 24 weeks in terms of rate of moderate-to-severe exacerbations and time to first moderate or severe exacerbation in groups of patients characterized by different serum interleukin-8 levels at baseline.
- Said patients were also characterized by different blood eosinophil count (number of eosinophil s/pl).
- the present invention relates to the use of blood IL-8 amount as a biomarker of response to a compound of formula (I).
- blood IL-8 value represents a predictive biomarker of enhanced clinical response to the compound of formula (I).
- Patients with a blood IL-8 value lower or equal to about 23 pg/ml are shown to have a higher clinical response to compound of formula (I) treatment as evidenced by a significant reduction of moderate- to-severe exacerbation rate and/or increased time to first moderate-to-severe exacerbation.
- the exacerbation rate reduction due to compound of formula I treatment in the overall population is -18%, while in patients with IL8 less or equal to about 23 pg/ml it is -27%, with IL8 less or equal to about 20 pg/ml it is -36 % and in patients with IL8 less than or equal to about 17 pg/ml it is -34%.
- Patient with lower serum IL-8 levels at baseline show augmented response to the compound of formula (I); the HR [95% CI] compared to placebo was 0.64 [0.41-1.01] for patients with IL8 lower than or equal to about 17 (17.3 pg/mL), 0.61 [0.40-0.93] for patients with IL8 lower than or equal to about 20 pg/mL, and 0.67 [0.46-0.97]; for patients with IL8 lower than or equal to about 23 pg/mL (Fig.3Al, A2, A3, respectively).
- IL-8 may be combined with at least one other biomarker, preferably blood eosinophils count.
- Patients with blood IL-8 value lower or equal to about 23 pg/ml and with blood eosinophil count higher or equal to about 150 cells/pl are shown to have a further enhanced response to the compound of formula (I), as demonstrated by a reduction of moderate-to-severe exacerbation rate and increased time to first moderate-to-severe exacerbation as shown in Fig 3C1-C3.
- the invention refers a method to identify a subject to be treated with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier wherein said subject is afflicted with a disorder susceptible to treatment with a PDE4 inhibitor, the method comprising the step of measuring the value of IL-8 and eosinophils value in the blood of the subject, and comparing the measured IL- 8 value and measured eosinophils value to a reference IL-8 and reference eosinophils value, respectively, wherein, if the IL-8 measured value is lower than or equal to the reference IL-8 value and the measured eosinophil value is higher than or equal to the reference eosinophil value, then the subject is identified.
- Inventors have also surprisingly found that patients with a chronic bronchitis phenotype and blood IL-8 value lower or equal to a reference value, have a further enhanced response to the compound of formula (I) as demonstrated by a reduction of moderate-to-severe exacerbation rate and by increased time to first moderate-to-severe exacerbation as shown in Fig. 3B1-B3.
- blood IL-8 as a biomarker provides a robust and reliable method to identify subjects with enhanced response to the compound of formula (I).
- the method of the present invention is particularly appreciated by the skilled person when looking at a suitable and efficacious way to personalize treatment with a PDE4 inhibitor, such as the compound of formula (I).
- the present invention relates to method for treating a subject with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier wherein the subject afflicted with a disorder susceptible to treatment with a PDE4 inhibitor, the method comprising the steps of: a) identifying a subject to be treated with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier according to the method as defined above and b) administering a therapeutic amount of a compound of formula (I) or the pharmaceutical composition to the subject.
- the disorder susceptible to treatment with a PDE4 inhibitor is a disease of the respiratory tract, preferably the disease is characterized by airway obstruction, still preferably the disease is asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the disorder susceptible to treatment with a PDE4 inhibitor is COPD.
- the value of IL-8 is a serum, plasma or PBMC concentration.
- the value of IL-8 is measured beforhands, i.e before starting the administration of the compound of formula (I), in order to better identify a suitable patient with higher likelihood to respond to the treatment.
- the measured value is lower than or equal to about 23 pg/ml.
- the measured value is lower than or equal to about 20 pg/ml.
- the measured value is lower than or equal to about 17 pg/ml.
- the method of the invention comprises a further step of measuring the value of eosinophils in the blood and comparing the measured value to a reference eosinophils value, wherein, if the measured eosinophils value is higher or equal to the reference eosinophils value, then the subject is identified or treated.
- the value of eosinophil is measured before starting the administration of the compound of formula (I).
- the eosinophils’ measured value is higher or equal to about 150 cells/pl.
- the method of the present invention is suitable to identify a patient population with enhanced response to compound of formula (I), said population being characterized by a serum IL-8 amount lower than or equal to about 23 pg/ml and a blood eosinophil count higher than or equal to about 150 cells/pl.
- the subject to be treated with the compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) and a pharmaceutically acceptable carrier is affected by COPD.
- the subject to be treated with the compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) and a pharmaceutically acceptable carrier is affected by COPD with a chronic bronchitis phenotype.
- the biomarkers as referred to herein can be detected using methods generally known in the art.
- the amount of a biomarker may be measured by contacting the sample with an agent that specifically binds to the biomarker, thereby forming a complex between the agent and said biomarker, detecting the amount of complex formed, and thereby measuring the amount of said biomarker.
- Methods of detection generally encompass methods to quantify the amount of a biomarker in the sample (quantitative method). It is generally known to the skilled artisan which of the following methods are suitable for qualitative and/or for quantitative detection of a biomarker. Samples can be conveniently assayed for, e.g., proteins using Westerns and immunoassays, like ELISAs, RIAs, fluorescence- and luminescence-based immunoassays, which are commercially available. Further suitable methods to detect biomarkers include measuring a physical or chemical property specific for the peptide or polypeptide such as its precise molecular mass or NMR spectrum.
- Said methods comprise, e.g., biosensors, optical devices coupled to immunoassays, biochips, analytical devices such as mass- spectrometers, NMR- analyzers, or chromatography devices.
- methods include microplate ELISA-based methods, fully-automated or robotic immunoassays (available for example on ElecsysTM analyzers), CBA (an enzymatic Cobalt Binding Assay, available for example on Roche-HitachiTM analyzers), and latex agglutination assays (available for ex- ample on Roche-HitachiTM analyzers).
- Examples of such methods include immuno-based assays, tandem Mass Spectrometry, isotopecoded protein labeling, protein microarrays, Proximity Extension Assays, immunoblotting, RN A- Sequencing, Microarray Gene Expression, real-time PCR, NanoString's nCounter.
- biomarker proteins For the detection of biomarker proteins as referred to herein a wide range of immunoassay techniques using such an assay format are available. These include both single-site and two-site or “sandwich” assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labeled antibody to a target biomarker.
- IL-8 is a biomarker and its amount shall be measured.
- the amount of the IL-8 polypeptide is measured.
- Seven isoforms are produced by proteolytic cleavage after cells secretion, namely:
- IL-8 may be measured by any method known in the art as protein or product of gene expression (mRNA) (Gene: CXCL8 ENSG00000169429) with different technologies.
- mRNA product of gene expression
- Measuring the amount of a polypeptide may, preferably, comprise the steps of (a) contacting the polypeptide with an agent that specifically binds said polypeptide (b) (optionally) removing non-bound agent, (c) measuring the amount of bound binding agent, i.e. the complex of the agent formed in step (a).
- said steps of contacting, removing and measuring may be performed by an analyzer unit.
- said steps may be performed by a single analyzer unit of said system or by more than one analyzer unit in operable communication with each other.
- said system disclosed herein may include a first analyzer unit for performing said steps of contacting and removing and a second analyzer unit, operably connected to said first analyzer unit by a transport unit (for example, a robotic arm), which performs said step of measuring.
- a transport unit for example, a robotic arm
- binding agent The agent which specifically binds the biomarker
- labeling agent may be coupled covalently or non-covalently to a label allowing detection and measurement of the bound agent.
- Labeling may be done by direct or indirect methods. Direct labeling involves coupling of the label directly (covalently or non- covalently) to the binding agent. Indirect labeling involves binding (covalently or non- covalently) of a secondary binding agent to the first binding agent.
- the secondary binding agent should specifically bind to the first binding agent.
- Said secondary binding agent may be coupled with a suitable label and/or be the target (receptor) of tertiary binding agent binding to the secondary binding agent.
- Suitable secondary and higher order binding agents may include antibodies, secondary antibodies, and the well-known streptavidin-biotin system (Vector Laboratories, Inc.).
- the binding agent or substrate may also be “tagged” with one or more tags as known in the art. Such tags may then be targets for higher order binding agents.
- Suitable tags include biotin, digoxygenin, His-Tag, Glutathion-S-Transferase, FLAG, GFP, myc-tag, influenza A virus haemagglutinin (HA), maltose binding protein, and the like.
- the tag is preferably at the N-terminus and/or C- terminus.
- Suitable labels are any labels detectable by an appropriate detection method.
- Typical labels include gold particles, latex beads, acridan ester, luminol, ruthenium complexes, iridium complexes, enzymatically active labels, radioactive labels, magnetic labels (“e.g. magnetic beads”, including paramagnetic and superparamagnetic labels), and fluo- rescent labels.
- Enzymatically active labels include e.g. horseradish peroxidase, alkaline phosphatase, beta-Galactosidase, Luciferase, and derivatives thereof.
- Suitable substrates for detection include di-amino- benzidine (DAB), 3,3'-5,5'-tetramethylbenzidine, NBT- BCIP (4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate, available as ready-made stock solution from Roche Diagnostics), CDP-StarTM (Amersham Bio- sciences), ECFTM (Amersham Biosciences).
- a suitable enzyme-substrate combination may result in a colored reaction product, fluorescence or chemo luminescence, which can be measured according to methods known in the art (e.g. using a light-sensitive film or a suitable camera system). As for measuring the enzymatic reaction, the criteria given above apply analogously.
- fluorescent labels include fluorescent proteins (such as GFP and its derivatives), Cy3, Cy5, Texas Red, Fluorescein, and the Alexa dyes (e.g. Alexa 568). Further fluorescent labels are available e.g. from Molecular Probes (Oregon). Also the use of quantum dots as fluorescent labels is contemplated.
- a radioactive label can be detected by any method known and appropriate, e.g. a light-sensitive film or a phosphor imager.
- the amount of a polypeptide may be, also preferably, measured as follows: (a) contacting a solid support comprising a binding agent for the polypeptide as described elsewhere herein with a sample comprising the peptide or polypeptide and (b) measuring the amount peptide or polypeptide which is bound to the support.
- Materials for manufacturing supports are well-known in the art and include, inter alia, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and/or silicon chips and surfaces, nitrocellulose strips, membranes, sheets, duracytes, wells and walls of reaction trays, plastic tubes etc.
- the sample may be removed from the complex formed between the binding agent and the at least one marker prior to the measurement of the amount of formed complex.
- the binding agent may be immobilized on a solid support.
- the sample can be removed from the formed complex on the solid support by applying a washing solution.
- Sandwich assays are among the most useful and commonly used assays encompassing a number of variations of the sandwich assay technique, including immune assays. Briefly, in a typical assay, an unlabeled (capture) binding agent is immobilized or can be immobilized on a solid substrate, and the sample to be tested is brought into contact with the capture binding agent. After a suitable period of incubation, for a period of time sufficient to allow formation of a binding agent-biomarker complex, a second (detection) binding agent labeled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of binding agent-biomarker-labeled bind- ing agent.
- any unreacted material may be washed away, and the presence of the biomarker is determined by observation of a signal produced by the reporter molecule bound to the detection binding agent.
- the results may either be qualitative, by simple observation of a visible signal, or may be quantitated by comparison with a control sample containing known amounts of bio marker.
- the incubation steps of a typical sandwich assays can be varied as required and appropriate. Such variations include for example simultaneous incubations, in which two or more of binding agent and biomarker are co-incubated. For example, both, the sample to be analyzed and a labeled binding agent are added simultaneously to an immobilized capture binding agent.
- the formed complex between a specific binding agent and the biomarker shall be proportional to the amount of the biomarker present in the sample. It will be understood that the specificity and/or sensitivity of the binding agent to be applied defines the degree of proportion of at least one marker comprised in the sample which is capable of being specifically bound. Further details on how the measurement can be carried out are also found elsewhere herein.
- the amount of formed complex shall be transformed into an amount of the biomarker reflecting the amount indeed present in the sample.
- Values or parameters which correlate with the amount comprise intensity signal values from all specific physical or chemical properties obtained from the said peptides by direct measurements, e.g., intensity values in mass spectra or NMR spectra. Moreover, encompassed are all values or parameters which are obtained by indirect measurements specified elsewhere in this description, e.g., response amounts measured from biological read out systems in response to the peptides or intensity signals obtained from specifically bound ligands. It is to be understood that values correlating to the aforementioned amounts or parameters can also be obtained by all standard mathematical operations.
- the comparison may be carried out manually or computer-assisted.
- the comparison may be carried out by a computing device.
- the value of the measured or detected amount of the biomarker in the sample from the subject and the reference amount can be, e.g., compared to each other and the said comparison can be automatically carried out by a computer program executing an algorithm for the comparison.
- the computer program carrying out the said evaluation will provide the desired assessment in a suitable output format.
- the value of the measured amount may be compared to values corresponding to suitable references which are stored in a database by a computer program.
- the computer program may further evaluate the result of the comparison, i.e. automatically provide the desired assessment in a suitable output format.
- the value of the measured amount may be compared to values corresponding to suitable references which are stored in a database by a computer program.
- the computer program may further evaluate the result of the comparison, i.e. automatically provides the desired assessment in a suitable output format.
- the amount of the biomarker IL-8 is compared to a reference.
- the reference is preferably a reference amount.
- a suitable reference amount may be determined from a reference sample to be analyzed together, i.e. simultaneously or subsequently, with the test sample.
- IL-8 may be measured in different biological samples such as blood, serum, plasma and PBMC.
- Samples of blood, plasma, serum, or derivative thereof can be obtained by well- known techniques. Separated cells may be obtained from blood, plasma, serum, or derivative thereof by separating techniques such as centrifugation or cell sorting.
- the sample may be frozen, fresh, centrifuged, etc.
- the sample can, of course, be subjected to a variety of well-known post-collection preparative and storage techniques (e.g., nucleic acid and/or protein extraction, storage, freezing, ultrafiltration, concentration, evaporation, centrifugation, etc.) prior to assessing the amount of the marker in the sample.
- IL-8 biomarker may be combined with at least another biomarker of response to the compound of formula (I): the blood eosinophils count.
- the blood eosinophils count is compared to a reference eosinophil value.
- Reference IL-8 value and reference eosinophil value are values measured before the beginning of administration of compound of formula (I) or a pharmaceutical composition thereof to a subject afflicted with a disorder susceptible to treatment with a PDE4 inhibitor.
- Eosinophils value or count may be measured by any method known in the art.
- eosinophils may be evaluated as part of standard hematology assessments by using Sysmex XT2000i analysers to provide results for all automated complete blood count testing (CBC).
- the Sysmex XT performs an automated white cell differential via flow cytometry methodology. Forward scattered light, lateral scattered light band lateral fluorescent light are detected via flow cytometry method utilizing a semiconductor laser and two dimensional scattergrams are drawn.
- the Sysmex analysers provide a 5-part white blood cell differential (neutrophils, lymphocytes, monocytes, eosinophils and basophils) reported in both percentages and absolutes.
- the Sysmex analysers utilise fluorescence flow cytometry. The sub-populations are separated on the basis of nucleic acid content and internal structure or complexity.
- Eosinophils in blood may also be measured with HemoCue® WBC Diff System (HemoCue AB, Angelholm, Sweden).
- the compound of formula (I) may be in the form of an inhalable dry powder formulation comprising particles of said compound and particles of a carrier made of a physiologically acceptable pharmacologically-inert material.
- patients may receive 1600 pg of the compound in the morning and 1600 pg in the evening for one year.
- Pharmaceutical acceptable carrier comprises a crystalline sugar selected from the group consisting of glucose, arabinose, maltose, saccharose, dextrose and lactose or a polyalcohol selected from the group consisting of mannitol, maltitol, lactitol and sorbitol, preferably lactose, even more preferably a-lactose monohydrate.
- composition may further comprise one or more additive materials selected form the group consisting of amino acids, water soluble surface active agents, lubricants and glidants, preferably magnesium stearate.
- disorders susceptible to treatment with a PDE4 inhibitor include: atopic dermatitis, allergic rhinitis, psoriasis and diseases of the respiratory tract, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and bronchiectasis.
- atopic dermatitis atopic dermatitis, allergic rhinitis, psoriasis and diseases of the respiratory tract, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and bronchiectasis.
- COPD chronic obstructive pulmonary disease
- COPD refers to a group of diseases that cause airflow blockage and breathing- related problems. It includes emphysema and chronic bronchitis or a mixed of both. COPD patients may have a emphysema phenotype, a chronic bronchitis phenotype or a mixed phenotype.
- the following examples illustrate the invention without limiting its scope.
- the compound of formula (I) was synthetized according to the methods as defined in WO 2015/059050, incorporated by reference. It can also be synthetized by any known method in the art.
- Objective of the present invention is to investigate the effect of the compound of formula (I) in comparison to placebo over 24 weeks in terms of rate of moderate-to-severe exacerbations and time to first moderate or severe exacerbation in groups of patients characterized by different serum interleukin-8 (IL-8) levels at baseline (randomization visit, prior to study treatment first intake) alone or within a group of patients characterized by a chronic bronchitis phenotype or patients characterized by different blood eosinophils count at baseline (randomization visit, prior to study treatment first intake)
- IL-8 serum interleukin-8
- IL-8 Blood for IL-8 determination was collected in the morning prior to the first treatment dose administration into serum separator tubes and kept at room temperature for 30-60 minutes to allow clotting. Samples were then centrifuged at 2000 g for 5 min at +4°C and serum transferred to the central laboratory at -60 to -90°C for analysis. IL- 8 was measured in serum with a validated Meso Scale Diagnostics (MSD) method using the MSD v-PLEX Plus kits (plate reader Mesoscale Discovery sector Imager 6000). The validation procedures followed was based upon those outlined in the ‘Guideline on Bioanalytical Method Validation’, EMA, CHMP, EWP, July 2011.
- MSD Meso Scale Diagnostics
- Assay validation comprised assessment of the calibration curve, establishment of endogenous concentration, validation control preparation, precision, parallelism/linearity of dilution, hook effect, stability and test article specificity.
- Calibration curve ranged from 0.0743 pg/mL to 687 pg/mL with 16-fold times linearity for dilution. Precision and accuracy (intra- and inter-assay) were within acceptance criteria. Stability in serum was demonstrated for up to 24 h at room temperature, after 4 freeze thaw cycles and up to 90 days, at nominally -80°C. All samples were analysed within 90 days from collection. The assay method was found to be accurate and precise and deemed suitable for measuring concentrations of IL-8 in human serum from regulatory studies.
- Eosinophils in blood may be measured by any method known in the art. Specifically eosinophils were evaluated as part of standard hematology assessments by using Sysmex XT2000i analysers to provide results for all automated complete blood count testing (CBC).
- CBC complete blood count testing
- the Sysmex XT performs an automated white cell differential via flow cytometry methodology. Forward scattered light, lateral scattered light band lateral fluorescent light are detected via flow cytometry method utilizing a semiconductor laser and two dimensional scattergrams are drawn.
- the Sysmex analysers provide a 5-part white blood cell differential (neutrophils, lymphocytes, monocytes, eosinophils and basophils) reported in both percentages and absolutes.
- the Sysmex analysers utilise fluorescence flow cytometry. The sub-populations are separated on the basis of nucleic acid content and internal structure or complexity.
- the rate of moderate or severe COPD exacerbation per patient per year was calculated for each treatment using a weighted approach (which consists of pooling all patients of a treatment group and dividing the total number of moderate or severe COPD exacerbations by the total follow-up time).
- the follow-up time in years was calculated using the following formula:
- Min minimum; Discontinued patients: patients who didn’t complete the study (i.e. 24 week observation).
- the moderate-to-severe COPD exacerbation rate and time to first moderate or severe exacerbation were analyzed in the overall population (including chronic bronchitis, emphysema and mixed phenotype) or in the chronic bronchitis phenotype (characterised by persistent cough and expectoration) only or in patients with higher blood eosinophil counts (EOS > 150 cells/ l).
- the analyses were repeated in subgroups of patients defined based on different IL-8 levels at baseline (e.g., patients with IL-8 value ⁇ threshold). Three different IL-8 thresholds were considered: about 17 pg/mL (17.3 pg/mL), about 20 pg/mL and about 23 pg/mL. Comparisons were performed using a significance level alpha of 0.05. All data were analysed using Statistical Analysis System software Version 9.4.
- the effect of the compound of formula (I) treatment is enhanced in patients having low serum IL-8 levels at baseline, specifically serum IL-8 levels at baseline below 23 pg/mL or below 20 pg /mL or below 17.3 pg/mL.
- the adjusted annualised moderate-to-severe exacerbation rates for patients with chronic bronchitis and serum IL-8 ⁇ 17.3 pg/mL, 20 pg/mL or 23 pg/mL ranged from 0.67 to 0.72 for placebo and from 0.36 to 0.43 for the compound of formula (I) (Fig.
- subjects with a chronic bronchitis phenotype and lower serum IL-8 concentration display a further increment of response to the compound of formula (I) also in terms of risk of experiencing a moderate-to-severe exacerbation over time.
- subjects with higher blood eosinophil count and lower serum IL-8 concentration display a further increment of response to the compound of formula (I) also in terms of risk of experiencing a moderate-to-severe exacerbation over time.
- blood IL-8 value represents a predictive biomarker of enhanced clinical response to the compound of formula (I).
- COPD patients with a blood IL-8 value lower or equal to a reference value are shown to have an increased response to the compound of formula (I) treatment in terms of moderate-to-severe exacerbation rate reduction as well as in the delay of the time to first moderate-to-severe exacerbation.
- biomarker may be combined with blood eosinophils counts.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention concerne l'utilisation de l'IL-8 comme biomarqueur de réponse clinique à un composé de formule (I), (I). L'invention concerne un composé de formule (I) ou une composition pharmaceutique associée destiné(e) à être utilisé(e) dans une méthode de traitement d'un trouble sensible au traitement avec un inhibiteur de PDE4, ladite méthode comprenant l'étape de mesure de la valeur de l'IL-8 dans le sang d'un sujet, ainsi qu'une méthode d'identification d'un sujet à traiter avec un composé de formule (I) ou une composition pharmaceutique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/071618 WO2024027901A1 (fr) | 2022-08-02 | 2022-08-02 | Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/071618 WO2024027901A1 (fr) | 2022-08-02 | 2022-08-02 | Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024027901A1 true WO2024027901A1 (fr) | 2024-02-08 |
Family
ID=83149022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/071618 WO2024027901A1 (fr) | 2022-08-02 | 2022-08-02 | Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024027901A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009018909A2 (fr) | 2007-08-08 | 2009-02-12 | Chiesi Farmaceutici S.P.A. | Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase |
WO2010089107A1 (fr) | 2009-02-06 | 2010-08-12 | Chiesi Farmaceutici S.P.A. | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase |
WO2012016889A2 (fr) | 2010-08-03 | 2012-02-09 | Chiesi Farmaceutici S.P.A. | Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase |
WO2015059050A1 (fr) | 2013-10-22 | 2015-04-30 | Chiesi Farmaceutici S.P.A. | Procédé de préparation d'un inhibiteur de la pde4 |
WO2020081866A1 (fr) * | 2018-10-18 | 2020-04-23 | Proterixbio, Inc. | Procédés d'évaluation et de traitement ciblés d'une maladie pulmonaire obstructive chronique et d'événements aigus et de la mortalité associés à ceux-ci |
RU2726228C1 (ru) | 2019-07-25 | 2020-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ отбора больных хронической обструктивной болезнью легких фенотипа "с редкими обострениями" для лечения рофлумиластом |
-
2022
- 2022-08-02 WO PCT/EP2022/071618 patent/WO2024027901A1/fr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009018909A2 (fr) | 2007-08-08 | 2009-02-12 | Chiesi Farmaceutici S.P.A. | Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase |
WO2010089107A1 (fr) | 2009-02-06 | 2010-08-12 | Chiesi Farmaceutici S.P.A. | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase |
WO2012016889A2 (fr) | 2010-08-03 | 2012-02-09 | Chiesi Farmaceutici S.P.A. | Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase |
WO2015059050A1 (fr) | 2013-10-22 | 2015-04-30 | Chiesi Farmaceutici S.P.A. | Procédé de préparation d'un inhibiteur de la pde4 |
WO2020081866A1 (fr) * | 2018-10-18 | 2020-04-23 | Proterixbio, Inc. | Procédés d'évaluation et de traitement ciblés d'une maladie pulmonaire obstructive chronique et d'événements aigus et de la mortalité associés à ceux-ci |
RU2726228C1 (ru) | 2019-07-25 | 2020-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ отбора больных хронической обструктивной болезнью легких фенотипа "с редкими обострениями" для лечения рофлумиластом |
Non-Patent Citations (5)
Title |
---|
"NCBI", Database accession no. NM_000584.4 |
"UniProtKB", Database accession no. P10145 |
FACCHINETTI FABRIZIO ET AL: "Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease", FRONTIERS IN PHARMACOLOGY, vol. 12, 23 November 2021 (2021-11-23), XP093029049, DOI: 10.3389/fphar.2021.740803 * |
KEATINGS ET AL., COMPARATIVE STUDY AM J RESPIR CRIT CARE MED, vol. 153, no. 2, February 1996 (1996-02-01), pages 530 - 4 |
SINGH DAVE ET AL: "Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD", RESPIRATORY RESEARCH, vol. 20, no. 1, 9 August 2019 (2019-08-09), XP055875532, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12931-019-1142-7/fulltext.html> DOI: 10.1186/s12931-019-1142-7 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3577465B1 (fr) | Proadm en tant que marqueur indiquant un événement indésirable | |
JP7104689B2 (ja) | 有害事象を示すマーカーとしてのヒストンおよび/またはproADM | |
JP2008545139A (ja) | 急性冠症候群の診断方法及び診断キット | |
JP7194673B2 (ja) | 臓器障害を示すマーカーとしてのヒストンおよび/またはproADM | |
Veerappan et al. | Mast cells and exosomes in hyperoxia-induced neonatal lung disease | |
CN115315523A (zh) | 使用无细胞核小体水平的分诊方法 | |
JP2023095851A (ja) | 抗生物質治療をモニタリングするためのマーカーとしてのpctおよびpro-adm | |
Lepissier et al. | Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge | |
JP2022521390A (ja) | 術後有害事象の診断または予後 | |
WO2024027901A1 (fr) | Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 | |
JP2021508045A (ja) | 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス | |
US20230160893A1 (en) | Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (sars) | |
EP3861347B1 (fr) | Biomarqueurs pour une polythérapie comprenant du lenvatinib et de l'évérolimus | |
TW202406543A (zh) | Pde4抑制劑臨床反應之預測性生物標記 | |
JP2022512590A (ja) | ソラフェニブ化合物を含む療法のためのバイオマーカー | |
RU2782305C2 (ru) | Про-адм в качестве маркера мониторинга терапии для критически больных пациентов | |
EP3682236A1 (fr) | Proadrénomédulline en tant qu'indicateur pour thérapie de remplacement rénal chez des patients gravement malades | |
RU2775090C2 (ru) | Проадреномедуллин в качестве маркера, указывающего на неблагоприятное событие | |
EP3985396A1 (fr) | Méthode de prédiction de pronostic de fibrose pulmonaire idiopathique | |
CN111065927B (zh) | 作为危重患者的治疗监测标记物的pro-adm | |
EP3928100B1 (fr) | Stratification de traitement pour une exacerbation d'inflammation | |
RU2788885C2 (ru) | Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками | |
TW201625946A (zh) | 5-甲氧基色胺酸作為發炎疾病診斷試劑之用途 | |
CN117529664A (zh) | 用于预测脓毒症和脓毒性休克的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22761442 Country of ref document: EP Kind code of ref document: A1 |